Communiqués Hologic, Inc.

Actions

HOLX

US4364401012

Marché Fermé - Nasdaq Autres places de cotation 22:00:01 06/06/2024			Varia. 5j.	Varia. 1 janv.
74,74 ^USD	+0,66 %		+2,98 %	+4,60 %

04/06	Transcript : Hologic, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 08:40 AM
29/05	Transcript : Hologic, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 10:00 AM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hologic : 2024 Leerink Partners Healthcare Crossroads Conference Transcript	29/05	PU
Hologic to Webcast Presentations at Upcoming Investor Conferences	21/05	BU
Hologic : Second Quarter Fiscal 2024 Earnings Conference Call Transcript	03/05	PU
Hologic : Second Quarter 2024 Transcript	03/05	PU
Hologic : Second Quarter 2024 Prepared Remarks	02/05	PU
Hologic: Fiscal Q2 Earnings Snapshot	02/05	AQ
Hologic Announces Financial Results for Second Quarter of Fiscal 2024	02/05	BU
Hologic : Statement on USPSTF Final Breast Cancer Screening Guidelines	30/04	PU
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company	29/04	BU
Hologic : Receives Innovative Technology Contract From Vizient for CoolSeal® Advanced Energy Portfolio and JustRight® 5 mm Stapler	16/04	PU
Hologic : to present at Needham Virtual Healthcare Conference Transcript	10/04	PU
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024	02/04	BU
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer	01/04	AQ
Hologic : Annual Meeting of Stockholders Proxy	07/03	PU
Hologic, Inc. - Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over or Undertreated Without Breast Cancer Index Genomic Testing	06/03	AQ
Hologic : to present at Raymond James' 45th Annual Institutional Investors Conference Transcript	06/03	PU
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing	05/03	BU
Hologic to Unveil Groundbreaking AI Research at ECR 2024	27/02	BU
Hologic to Webcast Presentations at Upcoming Investor Conferences	26/02	BU
Hologic : 2023Sustainability Report	13/02	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Hologic, Inc.

Actions

HOLX

US4364401012

Communiqués

Filtres